See more : Shanghai Aj Group Co.,Ltd (600643.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Nuvo Pharmaceuticals Inc. (MRVFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nuvo Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Airports of Thailand Public Company Limited (APTPF) Income Statement Analysis – Financial Results
- Satellos Bioscience Inc. (MSCL.V) Income Statement Analysis – Financial Results
- PT. Chandra Asri Petrochemical Tbk (PTCAY) Income Statement Analysis – Financial Results
- OmniLit Acquisition Corp. (OLITU) Income Statement Analysis – Financial Results
- 2U, Inc. (0LHP.L) Income Statement Analysis – Financial Results
Nuvo Pharmaceuticals Inc. (MRVFF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.miravohealthcare.com
About Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.
Nuvo Pharmaceuticals Inc (MRVFF) CEO Jesse Ledger on Q2 2021 Results - Earnings Call Transcript
Miravo Healthcare™ Announces Second Quarter 2021 Results
Miravo Healthcare™ Announces Second Quarter 2021 Results Release Date and Conference Call Details
Miravo Healthcare™ to Present at Access to Giving Virtual Investor Conference
Miravo Healthcare™ to Present at Summer Solstice - Best Ideas from the Buy Side
Miravo Healthcare™ Announces Appointment of Mary Ritchie to its Board of Directors
Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders
Miravo Healthcare™ Announces First Quarter 2021 Results
Miravo Healthcare™ to Present at Q2 Virtual Investor Summit
Miravo Healthcare™ Announces First Quarter 2021 Results Release Date and Virtual Annual Meeting of Shareholders
Source: https://incomestatements.info
Category: Stock Reports